Leonteq Securities AG Invests $928,000 in Teladoc Health, Inc. $TDOC

Leonteq Securities AG bought a new position in Teladoc Health, Inc. (NYSE:TDOC) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 132,512 shares of the health services provider’s stock, valued at approximately $928,000. Leonteq Securities AG owned approximately 0.07% of Teladoc Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Teladoc Health by 23.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after acquiring an additional 1,325,106 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Teladoc Health by 11.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after acquiring an additional 227,385 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Teladoc Health by 189.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after acquiring an additional 1,059,458 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Teladoc Health by 24.9% in the 3rd quarter. Bridgeway Capital Management LLC now owns 1,251,776 shares of the health services provider’s stock worth $9,676,000 after acquiring an additional 249,587 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TDOC has been the topic of several recent analyst reports. Citigroup boosted their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Oppenheimer dropped their price objective on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, March 3rd. Leerink Partners dropped their price objective on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating for the company in a research report on Thursday, February 26th. Wells Fargo & Company dropped their price objective on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, February 26th. Finally, Stifel Nicolaus dropped their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Thursday, February 26th. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teladoc Health presently has an average rating of “Hold” and an average target price of $7.53.

Insider Activity at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer owned 364,784 shares in the company, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.70% of the company’s stock.

Teladoc Health Stock Performance

TDOC stock opened at $6.55 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The company has a 50 day moving average price of $5.83 and a 200 day moving average price of $6.25. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.77. The stock has a market capitalization of $1.18 billion, a PE ratio of -6.75 and a beta of 2.08.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $613.85 million during the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The business’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Analysts forecast that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.